Movantik (naloxegol) works by blocking opioid receptors in your gut without affecting the pain relief opioids provide in your brain. It belongs to a class of drugs called peripherally acting mu-opioid receptor antagonists, or PAMORAs, designed specifically to treat opioid-induced constipation (OIC) in adults with chronic pain who aren’t getting relief from standard laxatives.
Why Opioids Cause Constipation
Opioid pain medications work by attaching to mu-opioid receptors throughout your body. In the brain, this attachment produces pain relief. But those same receptors also line your gastrointestinal tract, and when opioids bind to them there, they slow down the muscular contractions that move food through your intestines. Fluid absorption increases, stool hardens, and the normal signals that trigger a bowel movement get suppressed. The result is constipation that often doesn’t respond well to fiber, hydration, or standard laxatives, because the underlying cause is chemical rather than dietary.
How Movantik Reverses the Problem
Movantik is a modified version of naloxone, a well-known opioid blocker. It works by attaching to the same mu-opioid receptors in your gut wall that your pain medication occupies, effectively bumping the opioid off those receptors. Once the opioid is displaced, your intestines can resume their normal rhythm: muscle contractions restart, fluid secretion returns to normal, and stool begins to move.
The key difference between Movantik and a general opioid blocker like naloxone is that Movantik is engineered to stay out of your brain. It does this through a chemical modification called PEGylation, where a polyethylene glycol (PEG) chain is attached to the naloxone molecule. This PEG chain does two things. First, it makes the molecule too large to easily pass through cell membranes on its own. Second, it makes the molecule a target for a natural pump in the blood-brain barrier called the P-glycoprotein efflux transporter, which actively pushes the drug back out if it gets close to crossing into the brain. Together, these two properties keep Movantik working in the gut while your pain medication continues working in the brain, undisturbed.
How Effective It Is
In two large clinical trials (known as KODIAC-4 and KODIAC-5), patients taking the standard 25 mg dose had significantly more spontaneous bowel movements over 12 weeks compared to those on a placebo. In KODIAC-4, 44% of patients on Movantik had a consistent response versus 29% on placebo. In KODIAC-5, the numbers were 40% versus 29%. That means roughly 4 in 10 patients saw reliable improvement, which is meaningful for a condition that resists most other treatments, though it also means the medication doesn’t work for everyone.
Dosage and How to Take It
The recommended dose is 25 mg once daily, taken in the morning. If that dose causes too many side effects, your prescriber may lower it to 12.5 mg. People with reduced kidney function (creatinine clearance below 60 mL/min) typically start at the lower dose as well, with the option to increase if it’s well tolerated.
Timing matters. You need to take Movantik on an empty stomach, either one hour before your first meal of the day or two hours after it. Food can alter how much of the drug your body absorbs, so sticking to this schedule helps keep the dose consistent.
Common Side Effects
Because Movantik reactivates gut function that opioids have been suppressing, the most common side effects are gastrointestinal. In clinical trials of the 25 mg dose, 21% of patients reported abdominal pain (compared to 7% on placebo), 9% experienced diarrhea, and 8% had nausea. Flatulence, vomiting, and headache each occurred in 4% to 6% of patients. These side effects tend to reflect the gut “waking up” after being slowed down, and for many people they settle over time.
Patients taking methadone for pain had notably higher rates of GI side effects. In the 25 mg group, 75% of methadone users reported gastrointestinal reactions compared to 34% of patients on other opioids.
Opioid Withdrawal Risk
Since Movantik blocks opioid receptors, one natural concern is whether it could trigger withdrawal symptoms. The drug is designed to stay in the gut, but a small percentage of patients in clinical trials did experience withdrawal-like effects. At the 25 mg dose, about 3% of patients had clusters of symptoms (such as sweating, chills, anxiety, or irritability occurring on the same day) consistent with possible opioid withdrawal. At 12.5 mg, the rate was about 1%.
The risk rises in certain situations. Anyone with a condition that disrupts the blood-brain barrier, such as certain brain tumors or active central nervous system infections, faces a higher chance that the drug could reach the brain and interfere with pain relief or trigger withdrawal. Taking other opioid-blocking medications at the same time also increases risk.
Drug Interactions to Know About
Movantik is broken down in your body by a liver enzyme called CYP3A4. Anything that strongly blocks this enzyme can cause Movantik levels to spike, potentially triggering withdrawal symptoms. Strong CYP3A4 inhibitors, including the antibiotic clarithromycin and the antifungal ketoconazole, are contraindicated with Movantik entirely.
Moderate inhibitors of the same enzyme, such as the heart medications diltiazem and verapamil, or the antibiotic erythromycin, should be avoided when possible. If they can’t be stopped, the Movantik dose is typically reduced to 12.5 mg. On the other side of the equation, substances that speed up CYP3A4, like the supplement St. John’s Wort or the seizure medication carbamazepine, can lower Movantik levels enough to make it ineffective.
Grapefruit and grapefruit juice also inhibit CYP3A4 and should be avoided during treatment. The strength of this interaction varies depending on the brand and preparation of the juice, but some forms are potent enough to act as a strong inhibitor.
Who Should Not Take It
Movantik is specifically approved for opioid-induced constipation in adults with chronic non-cancer pain. It is not intended for people taking opioids short-term, such as after surgery. People with known or suspected gastrointestinal obstruction should not take it, as stimulating gut contractions against a blockage can be dangerous. Cases of bowel perforation have been reported with a related PAMORA drug, particularly in patients with conditions that weaken the intestinal wall, such as peptic ulcers or advanced illness with structural GI compromise.